Drug Most Volatile Stocks: Aerie Pharmaceuticals Inc (NASDAQ:AERI), Biostar Pharmaceuticals (NASDAQ:BSPM), Ventrus Biosciences (NASDAQ:VTUS), Retrophin (NASDAQ:RTRX)

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced that Vicente Anido, Jr., Ph.D., chairman and chief executive officer, will present at the 13th Annual Needham Healthcare Conference on Wednesday, April 9, 2014 at 12:10 pm Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview and business update. Aerie Pharmaceuticals Inc (NASDAQ:AERI) stock performance was -5.36% in last session and finished the day at $21.17. Traded volume was 66.30K shares in the last session and the average volume of the stock remained 96.26K shares. Aerie Pharmaceuticals Inc (NASDAQ:AERI) insider ownership is 2.50%.

Chinese pharmaceutical company Biostar Pharmaceuticals Inc (NASDAQ:BSPM) on Monday reported net income of USD809,046 for the fiscal year ended 31 December 2013. This reflects an improvement over the net loss of USD20m recorded in 2012. Biostar Pharmaceuticals Inc (NASDAQ:BSPM) dropped -5.48 percent to $2.07 Wednesday on volume of 283.50K shares. The intra-day range of the stock was $2.05 to $2.23. Biostar Pharmaceuticals Inc (NASDAQ:BSPM) has a market capitalization of $28.97million.

Ventrus Biosciences Inc (NASDAQ:VTUS) announced top line efficacy and safety results from the second Phase 3 clinical trial of Diltiazem Hydrochloride 2% Cream (VEN 307) in patients with pain related to anal fissure (AF). In this randomized double blind trial comparing diltiazem 2% cream versus placebo cream in 434 subjects in 90 centers globally, both treatment arms demonstrated a clinically meaningful improvement. Ventrus Biosciences Inc (NASDAQ:VTUS)’s stock on Apr 02, 2014 reported a increase of 3.36% to the closing price of $1.23. Its fifty two weeks range is $1.13 -$4.69. The total market capitalization recorded $25.66million. The overall volume in the last trading session was 598.3K shares. In its share capital, VTUS has 20.89million outstanding shares.

Retrophin Inc (NASDAQ:RTRX) CEO Martin Shkreli purchased 4,000 shares of Retrophin Inc (NASDAQ:RTRX) stock on the open market in a transaction that occurred on Monday, March 24th. The stock was purchased at an average cost of $17.61 per share, with a total value of $70,440.00. On Wednesday, shares of Retrophin Inc (NASDAQ:RTRX) advanced 8.85% to close the day at $23.36. Company monthly performance is recorded as 27.51%. Retrophin Inc (NASDAQ:RTRX) quarterly revenue growth is 238.06%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone